+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

In-Vitro Diagnostics Market by Component, Technology, Specimen, Application, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 180 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 4904897
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The In-Vitro Diagnostics Market grew from USD 109.05 billion in 2023 to USD 115.04 billion in 2024. It is expected to continue growing at a CAGR of 6.11%, reaching USD 165.27 billion by 2030.

In-Vitro Diagnostics (IVD) encompasses medical devices and reagents used in diagnosing diseases by examining biological samples outside the human body. The necessity of IVDs lies in their critical role in disease detection, monitoring health conditions, and guiding treatment decisions, making them indispensable in healthcare. Applications span across a variety of medical fields, including oncology, infectious diseases, metabolic disorders, and genetic testing. IVDs are utilized in numerous settings such as hospitals, diagnostic laboratories, academic institutions, and even home care, thus broadening their end-use scope. Key growth influencers include the increasing prevalence of chronic and infectious diseases, an aging population, and technological advancements such as digital pathology and AI-driven diagnostics. There is a surge in demand for personalized medicine and point-of-care testing, which promises notable market opportunities. Emerging areas such as liquid biopsy and genomics offer new avenues for innovation and market expansion. However, limitations include stringent regulatory requirements, high costs of development, and reimbursement challenges impacting market growth. Additionally, limited access to healthcare infrastructure in developing regions can pose further challenges. To capitalize on market opportunities, stakeholders should focus on developing cost-effective, rapid, and accurate diagnostic solutions. Collaborations and partnerships with tech companies can foster innovation, particularly in AI integration and data analytics. Engaging in R&D for new biomarkers and expanding test menus for multiplex assays also hold potential. The market is characterized by high competition with numerous established and emerging players, highlighting the importance of strategic differentiation through innovation and customization. Overall, while the IVD market has promising opportunities, companies need to navigate challenges effectively and invest in research and technological advancements to ensure sustained growth and competitive advantage.

Understanding Market Dynamics in the In-Vitro Diagnostics Market

The In-Vitro Diagnostics Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing prevalence of chronic and infectious diseases
    • Growing focus on personalized treatment coupled with increased adoption of companion diagnostics
    • Favourable government initiative for health awareness campaigns and screenings
  • Market Restraints
    • Lack of comprehensive reimbursement policies for certain diagnostic tests
  • Market Opportunities
    • Expansion of point-of-care testing coupled with growing healthcare infrastructure
    • Integration of diagnostics with digital health platforms
  • Market Challenges
    • Stringent regulations and approval processes associated with in vitro diagnostics

Exploring Porter’s Five Forces for the In-Vitro Diagnostics Market

Porter’s Five Forces framework further strengthens the insights of the In-Vitro Diagnostics Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the In-Vitro Diagnostics Market

External macro-environmental factors deeply influence the performance of the In-Vitro Diagnostics Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the In-Vitro Diagnostics Market

The In-Vitro Diagnostics Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the In-Vitro Diagnostics Market

The In-Vitro Diagnostics Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the In-Vitro Diagnostics Market

The In-Vitro Diagnostics Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the In-Vitro Diagnostics Market, highlighting leading vendors and their innovative profiles. These include 10x Genomics, Inc., Abbott Laboratories, Adaptive Biotechnologies Corp, Agilent Technologies Inc., Arkray Inc., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Biomérieux SA, Danaher Corporation, DiaSorin S.p.A., EKF GmbH, F. Hoffmann-La Roche Ltd., Grifols SA, Hologic, Inc., Illumina, Inc., Menarini Diagnostics, Mindray Medical International Limited, Myriad Genetics, Inc., Ortho-Clinical Diagnostics, Inc., Qiagen GmbH, Randox Laboratories, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the In-Vitro Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Component
    • Data Management Software & Services
    • Instruments
    • Reagents & Kits
  • Technology
    • Clinical Chemistry
      • Basic Metabolic Panel
      • Electrolyte Panel
      • Lipid Profile
      • Liver Panel
      • Renal Profile
      • Specialty Chemical Tests
      • Thyroid Function Panel
    • Coagulation & Hemostasis
    • Hematology
    • Immunochemistry
      • Enzyme-Linked Immunosorbent Assay
        • Chemiluminescence Immunoassays
        • Colorimetric Immunoassays
        • Fluorescence Immunoassays
      • Enzyme-Linked Immunospot Assays
      • Radioimmunoassay
      • Rapid Test
      • Western Blotting
    • Microbiology
    • Molecular Diagnostics
      • DNA Sequencing & Next-Generation Sequencing
      • Hybridization
      • Isothermal Nucleic Acid Amplification Technology
      • Microarray
      • Polymerase Chain Reaction
    • Urinalysis
  • Specimen
    • Blood, Serum & Plasma
    • Saliva
    • Urine
  • Application
    • Autoimmune Diseases
    • Cardiology
    • Diabetes
    • Drug Testing
    • HIV/Aids
    • Infectious Diseases
    • Nephrology
    • Oncology
  • End User
    • Hospitals & Care Providers
    • Laboratories
    • Patient Self-Testing
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of chronic and infectious diseases
5.1.1.2. Growing focus on personalized treatment coupled with increased adoption of companion diagnostics
5.1.1.3. Favourable government initiative for health awareness campaigns and screenings
5.1.2. Restraints
5.1.2.1. Lack of comprehensive reimbursement policies for certain diagnostic tests
5.1.3. Opportunities
5.1.3.1. Expansion of point-of-care testing coupled with growing healthcare infrastructure
5.1.3.2. Integration of diagnostics with digital health platforms
5.1.4. Challenges
5.1.4.1. Stringent regulations and approval processes associated with in vitro diagnostics
5.2. Market Segmentation Analysis
5.2.1. Component: The integral role of instruments, and reagents in in-vitro diagnostics
5.2.2. Application: Revolutionizing application of in-vitro diagnostic in cancer care
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. In-Vitro Diagnostics Market, by Component
6.1. Introduction
6.2. Data Management Software & Services
6.3. Instruments
6.4. Reagents & Kits
7. In-Vitro Diagnostics Market, by Technology
7.1. Introduction
7.2. Clinical Chemistry
7.2.1. Basic Metabolic Panel
7.2.2. Electrolyte Panel
7.2.3. Lipid Profile
7.2.4. Liver Panel
7.2.5. Renal Profile
7.2.6. Specialty Chemical Tests
7.2.7. Thyroid Function Panel
7.3. Coagulation & Hemostasis
7.4. Hematology
7.5. Immunochemistry
7.5.1. Enzyme-Linked Immunosorbent Assay
7.5.1.1. Chemiluminescence Immunoassays
7.5.1.2. Colorimetric Immunoassays
7.5.1.3. Fluorescence Immunoassays
7.5.2. Enzyme-Linked Immunospot Assays
7.5.3. Radioimmunoassay
7.5.4. Rapid Test
7.5.5. Western Blotting
7.6. Microbiology
7.7. Molecular Diagnostics
7.7.1. DNA Sequencing & Next-Generation Sequencing
7.7.2. Hybridization
7.7.3. Isothermal Nucleic Acid Amplification Technology
7.7.4. Microarray
7.7.5. Polymerase Chain Reaction
7.8. Urinalysis
8. In-Vitro Diagnostics Market, by Specimen
8.1. Introduction
8.2. Blood, Serum & Plasma
8.3. Saliva
8.4. Urine
9. In-Vitro Diagnostics Market, by Application
9.1. Introduction
9.2. Autoimmune Diseases
9.3. Cardiology
9.4. Diabetes
9.5. Drug Testing
9.6. HIV/Aids
9.7. Infectious Diseases
9.8. Nephrology
9.9. Oncology
10. In-Vitro Diagnostics Market, by End User
10.1. Introduction
10.2. Hospitals & Care Providers
10.3. Laboratories
10.4. Patient Self-Testing
11. Americas In-Vitro Diagnostics Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific In-Vitro Diagnostics Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa In-Vitro Diagnostics Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. Biocare Medical's Advanced Antigen Retrieval Chamber (ARC), Revolutionizing Immunohistochemistry
14.3.2. GenWorks Health launches IVD tests for dengue & malaria
14.3.3. Oxford Nanopore and bioMérieux to Enter Into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics
14.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. IN-VITRO DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 2. IN-VITRO DIAGNOSTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
FIGURE 7. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 9. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2023 VS 2030 (%)
FIGURE 11. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 13. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 15. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. IN-VITRO DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. IN-VITRO DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. IN-VITRO DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. IN-VITRO DIAGNOSTICS MARKET DYNAMICS
TABLE 7. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DATA MANAGEMENT SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BASIC METABOLIC PANEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ELECTROLYTE PANEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LIPID PROFILE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LIVER PANEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY RENAL PROFILE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIALTY CHEMICAL TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY THYROID FUNCTION PANEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COAGULATION & HEMOSTASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COLORIMETRIC IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSPOT ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY RADIOIMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY RAPID TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY WESTERN BLOTTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY BLOOD, SERUM & PLASMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY DRUG TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HIV/AIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY NEPHROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATIENT SELF-TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 89. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 90. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 91. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 92. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 93. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 94. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 95. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 96. CANADA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 98. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 99. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 100. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 101. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 102. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 103. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 104. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 105. MEXICO IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 116. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 117. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 118. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 119. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 120. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 122. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 124. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 126. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 127. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 128. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 129. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 130. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 131. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 132. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 133. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 134. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 136. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 137. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 138. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 139. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 140. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 141. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 142. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 143. CHINA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 145. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 146. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 147. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 148. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 149. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 150. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 151. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 152. INDIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 154. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 155. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 156. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 157. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 158. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 159. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 160. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 161. INDONESIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 163. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 164. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 165. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 166. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 167. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 168. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 169. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 170. JAPAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 172. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 173. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 174. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 175. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 176. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 177. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 178. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 179. MALAYSIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 181. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 182. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 183. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 184. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 185. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 186. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 187. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 188. PHILIPPINES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 190. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 191. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 192. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 193. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 194. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 195. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 196. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 197. SINGAPORE IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 199. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 200. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 201. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 202. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 203. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 204. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 205. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 206. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 208. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 209. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 210. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 211. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 212. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 213. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 214. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 215. TAIWAN IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 217. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 218. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 219. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 220. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 221. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 222. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 223. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 224. THAILAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 226. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 227. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 228. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 229. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 230. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 231. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 232. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 233. VIETNAM IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 244. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 245. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 246. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 247. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 248. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 249. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 250. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 251. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 252. DENMARK IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 254. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 255. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 256. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 257. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 258. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 259. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 260. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 261. EGYPT IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 263. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 264. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 265. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 266. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 267. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 268. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 269. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 270. FINLAND IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 271. FRANCE IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 272. FRANCE IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 273. FRANCE IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 274. FRANCE IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 275. FRANCE IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 276. FRANCE IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 277. FRANCE IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 278. FRANCE IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 279. FRANCE IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 280. GERMANY IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 281. GERMANY IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 282. GERMANY IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 283. GERMANY IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 284. GERMANY IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 285. GERMANY IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 286. GERMANY IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 287. GERMANY IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 288. GERMANY IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 289. ISRAEL IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 290. ISRAEL IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 291. ISRAEL IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 292. ISRAEL IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 293. ISRAEL IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 294. ISRAEL IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 295. ISRAEL IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 296. ISRAEL IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 297. ISRAEL IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 298. ITALY IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 299. ITALY IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 300. ITALY IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 301. ITALY IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 302. ITALY IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 303. ITALY IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 304. ITALY IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 305. ITALY IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 306. ITALY IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 307. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 308. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 309. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 310. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 311. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 312. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 313. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 314. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 315. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 316. NIGERIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 317. NIGERIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 318. NIGERIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 319. NIGERIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 320. NIGERIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 321. NIGERIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 322. NIGERIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 323. NIGERIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 324. NIGERIA IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 325. NORWAY IN-VITRO DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 326. NORWAY IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 327. NORWAY IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2030 (USD MILLION)
TABLE 328. NORWAY IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 329. NORWAY IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 330. NORWAY IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 331. NORWAY IN-VITRO DIAGNOSTICS MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
TABLE 332. NORWAY IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATIO

Companies Mentioned

The leading players in the In-Vitro Diagnostics market, which are profiled in this report, include:
  • 10x Genomics, Inc.
  • Abbott Laboratories
  • Adaptive Biotechnologies Corp
  • Agilent Technologies Inc.
  • Arkray Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories Inc.
  • Biomérieux SA
  • Danaher Corporation
  • DiaSorin S.p.A.
  • EKF GmbH
  • F. Hoffmann-La Roche Ltd.
  • Grifols SA
  • Hologic, Inc.
  • Illumina, Inc.
  • Menarini Diagnostics
  • Mindray Medical International Limited
  • Myriad Genetics, Inc.
  • Ortho-Clinical Diagnostics, Inc.
  • Qiagen GmbH
  • Randox Laboratories
  • Siemens AG
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.

Methodology

Loading
LOADING...

Table Information